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ABSTRACT Differential scanning calorimetry provides a newwindow into the plasma proteome. Plasma fromnormal individuals
yields a characteristic, reproducible thermogram that appears to represent the weighted sum of denaturation proﬁles of the most
abundant constituent plasma proteins. Plasma from diseased individuals yields dramatically different signature thermograms.
Thermograms from individuals suffering from rheumatoid arthritis, systemic lupus, and Lyme disease were measured. Each
disease appears to have a distinctive and characteristic thermogram. The difference in thermograms between normal and dis-
eased individuals is not caused by radical changes in the concentrations of themost abundant plasma proteins but rather appears
to result from interaction of as yet unknown biomarkers with the major plasma proteins. These results signal a novel use for cal-
orimetry as a diagnostic tool.
INTRODUCTION
The human plasma proteome is a complex fluid that contains
more than 3000 individual proteins and peptides that are
present in quantities that range from picograms to tens of
milligrams per milliliter (1–3). The human plasma proteome
holds great promise as a convenient specimen for disease
diagnosis and therapeutic monitoring (4–10). Blood samples
may be easily obtained from individuals who have given
informed consent by minimally invasive, safe procedures. A
number of FDA-approved plasma/serum diagnostic assays
are routinely used. These include serum plasma electropho-
resis (11) and a variety of immunochemical assays that can
monitor the concentrations of specific proteins in plasma/
serum. These existing low- to moderate-resolution assays
have had a profound practical impact on medical diagnosis.
For the medical practitioner, the measurement of plasma pro-
teins can be a powerful clinical assessment tool for detecting,
diagnosing, and monitoring diseases (12).
The recent explosion of proteomics has brought increased
interest in the human plasma/serum proteome as a source for
biomarkers of human disease. Higher-resolution methods
such as two-dimensional electrophoresis (13,14) and mass
spectrometry (5,15–18), coupled with often elaborate proto-
cols for sample preparation and fractionation, have made it
possible to identify apparent changes in the composition of
the less abundant proteins and peptides in plasma that seem
to correlate with particular diseases. Typically, no single pro-
tein emerges from such analyses as a wholly reliable biomarker,
but instead, changes in the patterns of panels of proteins often
serve as the best diagnostic for a particular malady. These
patterns often involve protein or peptide components of plasma
that are present in low concentrations.
Interest in the array of existing proteins in a patient’s serum
has thus evolved to a more detailed consideration of the low-
molecular-weight peptides within serum, which represent a
mixture of small intact proteins plus degradation fragments of
larger proteins. This low-molecular-weight region of the
serum proteome has been dubbed the ‘‘peptidome’’ (19) and
has been touted as a ‘‘treasure trove of diagnostic information
that has largely been ignored. . ..’’ (20).Mass spectrometry, in
particular SELDImethods,made the peptidome accessible for
analysis. (Others, however, have considered the peptidome to
be ‘‘unidentified flying peptides’’ and have questioned the
reliability of peptidome SELDI patterns as a meaningful di-
agnostic until the functions of all of the peptide peaks in the
peptidome have been properly identified (5).) Many compo-
nents of the ‘‘peptidome’’ were found to be complexed with
more abundant serum proteins, particularly human serum al-
bumin (HSA) and immunoglobulins. This led to the concept
of the ‘‘interactome’’ (21), which introduces the added com-
plexity that serum/plasma may be ‘‘comprised of a ‘network’
of protein-protein and peptide-protein interactions,’’ in which
potential biomarkers are bound to the more abundant proteins
within the fluid. Interestingly, the article that introduced the
‘‘interactome’’ concept concluded by saying that ‘‘the dis-
covery of novel biomarkers in serum/plasma requires new
biochemical and analytical approaches, and, most importantly,
it is clear that no single sample preparation or detectionmethod
will suffice if biomarker investigations are to be broadly suc-
cessful using current technologies’’ (21).We describe here an
entirely new technology for the analysis of the plasma/serum
proteomes.
Ten proteins make up 90% of the mass of plasma proteins
(by weight). These are, in order of abundance: albumin, IgG,
fibrinogen, transferrin, IgA, a2-macroglobulin, a1-antitryp-
sin, complement C3, IgM, and haptoglobin. Another 12
proteins account for another 9% of the plasma mass, the three
most abundant ofwhich are the apolipoproteinsA1 andB, and
a1-acid glycoprotein. Twenty-two proteins thus comprise
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99% of the mass of plasma, making it challenging to frac-
tionate and quantify the remaining 1%. Existing useful assays
monitor different aspects of the plasma proteome. The FDA-
approved serum protein electrophoresis monitors changes in
the most abundant protein population (11). More recent two-
dimensional gel electrophoresis and mass spectrometry assays
focus more on the least abundant components of plasma, fol-
lowing laborious prefractionation protocols to rid the plasma/
serum of the proteins present in high concentrations. What
is clear is that no single assay or technology can fully exploit
plasma as a source for biomarkers. Multiple technologies are
needed, each with a distinctive physical basis that can sense
unique properties of the individual proteins within the plasma
milieu. Electrophoresis and mass spectrometry, for example,
both separate plasma based on protein size and charge. Other
assays based on other physical properties of proteinswould be
useful adjuncts to current approaches for characterizing the
plasma proteome.
A novel calorimetric assay is described here that provides
a new window through which to view the properties of the
human plasma (or serum) proteome. Calorimetry provides a
direct means for detecting what is perhaps the most funda-
mental property of chemical and biochemical reactions, heat
changes. Biological calorimetry dates from the time of Lavoisier
(1743–1794), who invented a calorimetric method for mea-
suring the heats of metabolism of living animals (22). Our
assay exploits the high sensitivity of modern microcalorim-
eters, which can reliably measure heat changes of 0.1mcal. In
particular, we use the technique of differential scanning calo-
rimetry (DSC) (23–27).
A primary DSC thermogram is an extensive property of a
protein solution, and as such it is directly proportional to the
mass of the protein in solution. If the weight concentration of
the protein is doubled, for example, the calorimetric heat
response will double. Similarly, in a solution of mixtures of
proteins, the heat response will be proportional to the mass of
each protein component in the mixture. That is the funda-
mental basis of our assay and provides a distinct advantage.
Mixtures of proteins may be resolved with respect to the
fundamental characteristic denaturation profiles of their com-
ponent proteins. Each protein in a noninteracting mixture
will denature at its characteristic melting temperature (Tm)
and with its characteristic melting enthalpy. The observed
overall thermogramwill be, in the absence of interactions, the
weighted sum of all of the individual protein thermograms,
weighted according to the mass of each component. DSC has
an added advantage. Binding interactions can alter the thermal
denaturation of proteins in ways that are nowwell understood
(24,28). If the ‘‘interactome’’ hypothesis (21) is correct, calo-
rimetrywould beuniquely sensitive to the proposedbiomarker-
protein interactions in plasma inways that electrophoresis and
mass spectrometry are not.
We show that DSC provides an entirely new window into
the plasma proteome. Plasma from normal individuals yields
a reproducible and characteristic thermogram. Unique sig-
nature thermograms are obtained from the plasma from dis-
eased individuals, indicating the potential of calorimetry as a
new type of clinical diagnostic.
MATERIALS AND METHODS
Pure protein samples
HSA (lot No. 113K7601), immunoglobulin G (IGG) (lot No. 415781/1),
immunoglobulin A (IGA) (lot No. 105K3777), a1-acid glycoprotein (AAG)
(lot No. 073K7607), a1-antitrypsin (AAT) (lot No. 033K7603), fibrinogen
(FIB) (lot No. 083K7604), transferrin (TRF) (lot No. 123K14511), hapto-
globin (HPT) (lot No. 055K1664), and immunoglobulin M (IGM) (lot
No. 016K4876) were purchased from Sigma-Aldrich (St. Louis, MO).
a1-Antichymotrypsin (ACT) (lot No. B58700), complement C3 (C3) (lot No.
D33204), complement C4 (C4) (lot No. D34721), ceruloplasmin (CER) (lot
No. B70322), a2-macroglobulin (A2M) (lot No. B73605), and prealbumin
(PRE) (lot No. B68296) were purchased from Calbiochem (LaJolla, CA).
C-reactive protein (CRP) (lot No. 32F0305FP) was purchased from Life
Diagnostics (West Chester, PA).
Standard reference serum
A serum reference material (sample No. 16910) was purchased from Sigma-
Aldrich.
Plasma samples
Normal plasma samples (lot Nos. JA053759, JA053761, JA053763, JA053764,
JA053765, JA053766, JC014372, JM034968, JM034969, JM034970,
JM034971) were purchased from Innovative Research (Southfield, MI) and
were also obtained from the Gynecological Cancer Repository of the James
GrahamBrownCancer Center. Plasma from individuals suffering fromLyme
disease (lot Nos. BM146897, BM140032, BM140031, BM140028), sys-
temic lupus erythematosis (lot Nos. BM142168, BM142160), and rheuma-
toid arthritis (lot Nos. BM204810, BM205222, BM203373, BM202803,
BM200182)were purchased fromBBIDiagnostics (West Bridgewater,MA).
Institutional approval
All studies utilized deidentified plasma samples using protocols and proce-
dures reviewed and approved by the University of Louisville Human Sub-
jects Protection Program Office (studies 177.07 and 608.03).
Sample preparation
IGM, C3, C4, and CRP were purchased as solutions in buffer, lyophilized to
dryness, and then reconstituted in a smaller volume of ultrapure water (18.2
MV-cm) to yield a concentration suitable for DSC. PRE, A2M, CER, and
ACT were purchased as powders lyophilized from buffer and were recon-
stituted with ultrapure water. HSA, IGG, IGA, AAG, AAT, FIB, TRF, and
HPT were reconstituted with 10 mM potassium phosphate, 150 mM NaCl,
pH 7.5. Reference serum was reconstituted according to the guidelines. Pure
proteins and reference serum were dialyzed for 24 h at 4C against 10 mM
potassium phosphate, 150 mMNaCl, pH 7.5, to ensure complete solvent ex-
change. Pure protein samples were diluted with dialysate to a concentration
suitable for DSC. Reference serum was diluted 25-fold with the dialysate.
Plasma samples (100 ml) were dialyzed for 24 h at 4C against 10 mM
potassium phosphate, 150 mMNaCl, 0.38% (w/v) sodium citrate, pH 7.5, to
ensure complete solvent exchange and then diluted 25-fold with the same
buffer. All samples (0.45 mm, cellulose acetate or polyethersulfone) and
buffers (0.22 mm, polyethersulfone) were filtered before use. Pure protein
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concentrations were quantified spectrophotometrically using the following
extinction coefficients (e280; liter
1gcm1): HSA, 0.53; IGG, 1.38; IGA,
1.32; AAG, 0.89; AAT, 0.53; FIB, 1.55; TRF, 1.12; HPT, 1.2; IGM, 1.18;
ACT, 0.62; C3, 0.97; C4, 0.92; CER, 1.49; A2M, 0.893; PRE, 1.41; CRP,
1.95.
DSC protocol
Scans were performed using an automated capillary DSC (MicroCal,
Northampton, MA). Samples and dialysate were stored in 96-well plates at
5C until being loaded into the calorimeter by the robotic attachment. Scans
were recorded from 20C to 110C at 1C/min using the mid feedback mode,
a filtering period of 2 s, and with a prescan thermostat of 15 min. Data were
analyzed using Origin 7.0. Sample scans were first corrected for the instru-
ment baseline by subtracting an appropriate buffer scan. Nonzero baselines
were then corrected by applying a linear baseline fit. Scans were finally nor-
malized for the gram concentration of protein. For the pure protein samples,
protein concentrations were determined spectrophotometrically as outlined
above. Total protein concentrations of the reference serum and plasma sam-
ples were measured by the bicinchoninic acid method (Pierce, Rockford, IL).
Thermograms were plotted as excess specific heat capacity (cal/Cg) versus
temperature.
Clinical assay methods
Protein electrophoresis was performed on agarose gels using the SPIFE 3000
and scanned with the QUICKSCAN 2000 (Helena Laboratories, Beaumont,
TX). Total protein was measured by the biuret method on the Ortho Vitros
950 (Vitros) (Ortho-Clinical Diagnostic, Rochester, NY) chemistry analyzer.
Albumin was measured on the Vitros by the bromocresol green dye binding
assay or by an immunoturbidometric assay on the Cobas Integra 800 (Roche,
Indianapolis, IN). Albumin concentrations were also determined from the
fraction percentage on the protein electrophoresis assay along with the total
protein concentration. Specific serum proteins (IGG, IGA, TRF, HPT, IGM,
C3, C4, PRE, CRP) were measured by immunoturbidimetry on the Integra.
Column depletion experiments
Reference serum was depleted of HSA using the SwellGel Blue albumin
removal kit with some minor modifications to the manufacturer’s protocol
(Pierce, Rockford, IL). The serum sample was diluted 10-fold into 10 mM
potassium phosphate, pH 7.5, to achieve salt conditions and albumin con-
centrations required for good column binding. Diluted serum (200 ml) was
applied to a column containing two SwellGel disks. An HSA-depleted frac-
tionwas obtained following the standard protocol. A single 200-ml volume of
the supplied binding/wash buffer was used to obtain a wash fraction. Finally,
an eluted HSA fraction was obtained from a single 200-ml addition of the
supplied elution buffer. To obtain a greater volume of each fraction for sub-
sequent experiments, multiple columns were run using an identical protocol,
and all of the fractionswere pooled. Fractions for DSC analysis were dialyzed
for 24 h at 4C against 10 mM potassium phosphate, 150 mM NaCl, pH 7.5,
and diluted as necessary with dialysate. DSC scans were performed on an
N-DSC II instrument (Calorimetry Sciences, Provo, UT) from 20C to 110C
at 1C/min with a prescan equilibration time of 10 min. Data were analyzed
using Origin 7.0 as described above.
RESULTS AND DISCUSSION
Thermogram for normal plasma
Fig. 1 shows an average thermogram obtained from plasma
samples from 15 normal individuals. The thermogram dis-
plays multiple peaks and shoulders yet is surprisingly simple,
given the complexity of the plasma proteome. The standard
deviation of the data (shaded area in Fig. 1) is low and is
comparable to the range in values observed in normal indi-
viduals for the concentrations of individual plasma proteins
(12). Human serum albumin, for example, has a normal ref-
erence range of;35–55 g/liter, dependent on age and gender
(12). The average normal thermogram in Fig. 1 shows clear
peaks at 50.8, 62.8, and 69.8C. The area under the thermo-
gram is 5.026 0.23 cal g1 and defines the specific enthalpy
for the denaturation of normal plasma over the range 45–
90C. The first moment of the thermogram with respect to
the temperature axis is 67.4 6 0.8C. The sample size used
in these studies is appropriate for exploratory preclinical
studies and, indeed, is on a par with the numbers expected for
a Phase I clinical trial (29), although that is not our current
aim.
The normal plasma thermogram is the
weighted sum of the denaturation of individual
plasma proteins
Wehypothesize that the thermogram seen in Fig. 1 arises from
the denaturation of the individual proteins within plasma and
represents the sum of individual protein denaturation reac-
tionsweighted according to their concentrationswithin plasma.
We tested this hypothesis in two ways, as shown in Fig. 2.
First, individual thermograms for the denaturation of the 16
most abundant plasma proteins were determined (Supple-
mentary Fig. 1). These thermograms display a range of de-
naturation temperatures and differences in the complexities of
their denaturation reactions.Many of these thermograms show
multiple peaks, indicative of complex denaturation reactions,
FIGURE 1 DSC thermogram of normal plasma. The solid line is the
average of 15 thermograms of plasma samples from 15 individuals (9 male,
6 female; ages 22–50). The shaded area is the standard deviation at each
temperature. The vertical dashed line is the first moment of the thermogram
at 67.4C.
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whereas other thermograms are consistent with simple two-
state melting behavior. Fig. 2 A shows the calculated plasma
thermogram obtained by simple summation of the individual
thermograms for the 16 most abundant plasma proteins after
their contributions were weighted according to their known
average concentrations in normal plasma (12). A tacit assump-
tion in this exercise is that there are no interactions among
these proteins that might alter their thermal denaturation. The
resultant shape of the calculated thermogram mimics that of
the experimental one seen in Fig. 1, in support of our hy-
pothesis. As a second test, mixtures of pure individual plasma
proteins were prepared, and their thermograms determined by
DSC (Fig. 2 B). A mixture containing the 16 most abundant
plasma proteins at their average concentrations found in nor-
mal plasma yields a thermogram whose shape mimics that of
actual plasma (Fig. 2 B). A mixture with only the four major
components (HSA, IgG, fibrinogen, and transferrin) yields a
thermogram that closely matches the observed normal but
lacks subtle features (Fig. 2B). The data in Fig. 2 show that the
normal thermogram is dominated by contributions from those
four proteins. The small peak at 50.8Ccan be unambiguously
assigned to a transition in fibrinogen. Themajor peak at 62.8C
primarily reflects the denaturation of unligated HSA, with a
contribution from haptoglobin. The peak at 69.8C and the
shoulders at higher temperature arise primarily from IgG.
Thermograms of HSA-depleted serum
Supplementary Fig. 2 shows the results from experiments in
which albumin was removed from serum by affinity chro-
matography. (Serum differs from plasma primarily by the
absence of fibrinogen, which is removed when plasma is
allowed to clot.) Supplementary Fig. 2 A shows the expected
thermogram obtained by calculating the weighted sum of the
most abundant proteins minus HSA and fibrinogen. Supple-
mentary Fig. 2 B shows the observed experimental thermo-
gram for albumin-depleted serum. The agreement between
the shape of the calculated and observed thermograms is ex-
cellent. Apart from confirming the major contribution by HSA
to the peak at 62.8C in plasma thermograms, these data show
that the contributions of other plasma proteins to thermo-
grams can be amplified for more detailed study.
Plasma thermograms from diseased
individuals differ dramatically from those
of normal individuals
Fig. 3 compares average thermograms for individuals with
three different diseases (rheumatoid arthritis, Lyme disease,
systemic lupus) with the average normal thermogram. In all
cases, dramatic differences from normal are evident. In
addition, each disease seems to display a signature thermo-
gram that differs from those of other diseases. In all cases,
the 62.8C peak associated with HSA is greatly diminished,
and the thermograms are shifted to higher temperatures. Fig.
3 A shows the thermogram for lupus. The first moment shifts
from the normal value of 67.5C to a value of 71.5C. A
sharp peak near 61C is evident that would be consistent
with an elevation in haptoglobin concentration. The ther-
mogram for Lyme disease (Fig. 3 B) is distinct from that seen
for systemic lupus. The first moment at 73.15C is higher
still, and the shape of the thermogram clearly differs from
both normal and lupus thermograms. Fig. 3 C shows yet
another distinctive thermogram for individuals suffering
from rheumatoid arthritis. That thermogram is characterized
by a first moment of 67.9C, only slightly higher than normal,
but with distinct changes in the shape relative to normal that
are well beyond the standard deviations in the two thermo-
grams. These collective results indicate the potential of DSC
as a clinical diagnostic tool, providing a unique window into
the plasma proteome. Thermograms can at a glance distin-
guish diseased states from normal and can potentially pro-
vide signatures for specific diseases. The latter possibility, of
course, can not be confirmed until a more systematic and
comprehensive study of multiple diseases is undertaken. The
sample sizes used in these studies conform to the accepted
standards for exploratory preclinical studies (29).
FIGURE 2 Origin of the plasma thermogram. (A) Calculated thermogram
(dashed line) obtained from the sum of the weighted contributions of the 16
most abundant plasma proteins. Thermograms for the individual pure plasma
proteins are shown in Fig. 3 of the Supplementary Material). (B) Thermo-
grams obtained from mixtures of pure plasma proteins, mixed at concentra-
tions that mimic their known average concentrations in normal plasma. The
red curve is a mixture of HSA, IgG, fibrinogen, and transferrin. The black
curve is a mixture of the 16 most abundant plasma proteins.
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Origin of the altered thermograms
What causes the dramatic alterations in thermograms seen in
Fig. 3? One possibility is that the concentrations of the major
proteins in plasma are changed. This possibility was tested
by experiments shown as Supplementary Material that in-
dicate that such is not the case. Supplementary Fig. 3 shows
the concentrations of the major plasma proteins for the same
samples shown in Fig. 3. The data show that the protein com-
position of plasma from diseased individuals is in most case
indistinguishable from normal concentration values. Plasma
from lupus patients represents a slight exception, with sam-
ples showing elevated concentrations of haptoglobin, IgA,
and IgM. Notably, albumin concentrations are normal for all
of the diseased states, even though the thermogram peak at
62.8C that is characteristic of albumin is absent or greatly
diminished in diseased samples (Fig. 3). Supplementary Fig.
4 shows protein electrophoresis patterns for normal plasma
and the diseased states. Only subtle variations can be seen
when these traces are compared, in contrast to the dramatic
shifts in thermograms seen in Fig. 3. These data reveal a dis-
tinct advantage of our calorimetric approach. Although what-
ever is present in plasma in the diseased state that differentiates
samples from normal does not seem to drastically alter the
concentrations or the sizes and charges of the plasma pro-
teins (as revealed by electrophoresis), it does exert dramatic
effects on the thermal properties of the proteins.
The most likely explanation for the shifts in the thermo-
grams in Fig. 3 is that they result from binding interactions
that involve the most abundant plasma proteins, particularly
albumin. This view is consistent with the ‘‘interactome’’ hy-
pothesis, which suggests that peptide and protein biomarkers
specific for a particular disease are not free in plasma but
rather are bound to albumin or the immunoglobins. Such
binding would result in thermal stabilization of the protein to
which the biomarkers are bound and a drastic alteration of the
plasma thermogram with respect to normal. That is exactly
what is seen in Fig. 3. A definitive test of this model is pro-
hibitively difficult at this point. In principle, one could isolate
the ligated proteins from diseased plasma, wash off the bound
biomarkers, and purify them.These purified biomarkers could
then be added to normal plasma to demonstrate the charac-
teristic alteration in the thermogram. Similar laborious fractiona-
tion procedures are routinely attempted in mass spectrometry
studies that attempt to probe the plasma ‘‘interactome’’ in
search of biomarkers, but on a preparative scale that yields
amounts of material that are orders of magnitude lower than
would be needed for calorimetric studies.
To test the hypothesis that shifted thermograms result
from interactions, we designed an alternative demonstration.
Bromocresol green is known to bind to Site I of HSA with a
binding constant of 7 3 105 M1 (30). Its binding to HSA
within normal plasma ought to mimic the effects of putative
biomarker binding. Fig. 4 shows the results of the experiment.
Fig. 4 A shows difference thermograms for diseased states,
obtained by subtracting the normal thermograms from the
average thermograms seen in Fig. 3. These difference plots
feature a negative peak near 62C, attributable to a shift in
HSA denaturation to higher temperatures. Positive difference
peaks are evident at 70C and higher, attributable to dena-
turation of ligated HSA (or other proteins). Such behavior
can be mimicked by addition of bromocresol green (Fig. 4
B). Fig. 4 B shows a difference thermogram calculated from
normal plasma samples with and without added bromocresol
green. (More details of experiments showing the effects of
bromocresol green on plasma and pure HSA are shown in
Supplementary Fig. 5.) The shape of the difference thermo-
gram is qualitatively similar to those seen for diseased plasma
samples, suggesting that the ‘‘interactome’’ hypothesis has merit
and provides a plausible explanation for shifts in thermograms
observed in Fig. 3.
The shifts in denaturation transition curves that accom-
pany ligand binding to protein are well understood and have
been explained by a number of specific statistical mechanical
and thermodynamic models (24,28). The effects of binding
on the magnitude and exact shape of a melting transition curve
depend precisely on the ligand binding affinity, enthalpy, and
stoichiometry. Complex multiphasic transition curves can
FIGURE 3 Thermograms of plasma from diseased individuals. Each panel
compares normal plasma (magenta shading) with diseased plasma (cyan
shading). The average thermogram is shown as a solid line; the shading
indicates the standard deviation. (A) Plasma from individuals with systemic
lupus. The averagewas obtained from four thermograms, duplicate DSC runs
on samples from two diseased individuals. (B) Plasma from individuals with
Lyme disease. The average was obtained from eight thermograms, duplicate
DSC runs on samples from four diseased individuals. (C) Plasma from
individuals with rheumatoid arthritis. The average was obtained from 10
thermograms, duplicate DSC runs on samples from five diseased individuals.
Each panel shows the first moment of the thermogram as vertical solid
lines—magenta for normal, and cyan for the disease.
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result from partial saturation. It is easy to imagine that peptide
biomarkers in plasma might produce a myriad of thermogram
shapes, depending on the exact proteins (and protein binding
sites) that they occupy and their affinities. The interactions of
multiple unique biomarkers with different plasma proteins
could produce unique, characteristic thermograms that reflect
the underlying complexity of the interactions. Although calo-
rimetry may not sense signals arising from the denaturation
of the biomarkers themselves, it would be uniquely sensitive
to interactions of these biomarkers with the more abundant
plasma proteins.
CONCLUSIONS
DSC provides a newwindow into the plasma proteome. Ther-
mogramsobtained for plasma samples fromnormal individuals
yield a reproducible, characteristic signature that represents
the weighted sum of denaturation profiles of the constituent
proteins. Thermograms of plasma from diseased individuals
differ dramatically from normal, and from one another, for the
three diseases examined (arthritis, Lyme disease, and lupus).
The radically different thermograms seen for diseased states
are not consequences of major changes in the concentrations
of the major constituent plasma proteins but, rather, seem to
arise from binding interactions involving as yet unknown
biomarkerswith themore abundant plasmaproteins, particularly
albumin. Such behavior is consistent with the ‘‘interactome’’
hypothesis. These results portend a novel application of calo-
rimetry as a clinical diagnostic tool.
SUPPLEMENTARY MATERIAL
To view all of the supplemental files associated with this
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